Scarica l'app Stockscreener
72.10
4.03%
-3.03
Dopo l'orario di chiusura:
72.10
Precedente Chiudi:
$75.13
Aprire:
$75.21
Volume 24 ore:
1.42M
Relative Volume:
1.22
Capitalizzazione di mercato:
$3.53B
Reddito:
-
Utile/perdita netta:
$-192.89M
Rapporto P/E:
-18.50
EPS:
-3.8976
Flusso di cassa netto:
$-172.97M
1 W Prestazione:
-9.33%
1M Prestazione:
-25.05%
6M Prestazione:
-35.99%
1 anno Prestazione:
+45.89%
Intervallo 1D:
$70.67
$75.44
Intervallo di 1 settimana:
$70.67
$88.68
Portata 52W:
$45.03
$151.02
Celcuity Inc Stock (CELC) Company Profile
Nome
Celcuity Inc
Settore
Industria
Telefono
763-392-0767
Indirizzo
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
72.10 | 3.89B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Citizens | Mkt Outperform |
| 2025-12-12 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Stifel | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-02-22 | Iniziato | Stifel | Buy |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-07 | Iniziato | Jefferies | Buy |
| 2021-07-29 | Iniziato | Cowen | Outperform |
| 2021-07-27 | Iniziato | Needham | Buy |
| 2021-01-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-11 | Ripresa | Craig Hallum | Buy |
| 2018-11-20 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Celcuity Inc Borsa (CELC) Ultime notizie
CELCUITYANNOUNCES REVTORPYK NOW COMMERCIALLY AVAILABLE IN THE UNITED STATES - Moomoo
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Why Celcuity Stock Was a Winner on Wednesday - The Motley Fool
Why Celcuity Stock Was a Winner on Wednesday - The Motley Fool
Celcuity Inc. Announces REVTORPYK? (Gedatolisib) Is Commercially Available In The United States - marketscreener.com
Liquidity Mapping Around (CELC) Price Events - Stock Traders Daily
Needham maintains Buy rating on Celcuity, $134 price target - TradingView
Celcuity launches Revtorpyk for advanced breast cancer in US By Investing.com - Investing.com South Africa
Celcuity launches Revtorpyk for advanced breast cancer in US - Investing.com
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States - The Manila Times
7VR Forecast — Price Target — Prediction for 2027 - TradingView
ETFs Investing in Celcuity Inc. Stocks - TradingView
Is Celcuity (CELC) Stock a Buy? - Yahoo Finance
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Stocktwits
Celcuity Inc.Common Stock (NQ: CELC - The Chronicle-Journal
Celcuity Inc. (CELC) Stock Analysis: Unpacking An 89.32% Potential Upside In Biotech - DirectorsTalk Interviews
Celcuity Inc. (CELC) Key Financial Ratios – Valuation, Profitability & More - Value Research
Celcuity, Fluence Energy, Salesforce - tradingview.com
CELC Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
Celcuity Initiated at Overweight by JP Morgan - Moomoo
JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target - marketscreener.com
JPMorgan initiates Celcuity stock coverage with overweight rating By Investing.com - Investing.com India
JPMorgan initiates Celcuity stock coverage with overweight rating - Investing.com
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Trading Systems Reacting to (CELC) Volatility - Stock Traders Daily
Transcript : Celcuity Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Celcuity at citigroup’s biopharma back to school summit: launch begins By Investing.com - Investing.com India
Celcuity at Wells Fargo healthcare conference: launch, data in focus By Investing.com - Investing.com Canada
Celcuity Stock Price Forecast. Should You Buy CELC? - StockInvest.us
Celcuity (CELC) Could Be 40% Undervalued After REVTORPYK FDA Filing - simplywall.st
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer - Simply Wall Street
What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer? - simplywall.st
Celcuity (CELC): Landmark Approval Collides With A Costly Launch - Yahoo Finance
Celcuity submits application for breast cancer drug expansion - Investing.com
Celcuity’s three-drug breast cancer treatment cut progression or death risk 50% vs. alpelisib - Stock Titan
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer - Yahoo Finance
Celcuity (CELC) Technicals: Finishes 2.93% Down at $90.79 in the Latest Reading; Levels: Price Remains Between $86.25 Support and $95.33 ResistanceSpring Pattern - careplusvn.com
Celcuity Inc (CELC) Stock News Today - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call Transcript - AOL.com
Celcuity (CELC) Quarter in Focus: EPS Comes in Below Forecast in the Current Update; Closing Move: Shares Move 2.79% Down in the Available RecordEarnings Weakness Phase - vinanet.vn
E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ: CELC) insider updates stock holdings - Stock Titan
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating, Cuts Target Price to $173 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp - MarketBeat
Celcuity awaits FDA review for second factory to launch cancer drug - Endpoints News
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Nigeria
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com South Africa
Celcuity Inc Azioni (CELC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):